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The current standard treatment for locally advanced rectal cancer (LARC) in Korea 
and Western countries is a multimodal approach incorporating preoperative long-
course chemoradiotherapy (LCRT) followed by total mesorectal excision (TME) and 
adjuvant chemotherapy. This approach has significantly improved local control and 
reduced recurrence rates; however, the overall survival benefit has not been estab-
lished. Although LCRT is a good option, there remain challenging unresolved prob-
lems for colorectal surgeons. We focused on four challenging issues in this review 
article. The first is LARC with resectable liver metastases, for which there has been 
no consensus regarding optimal management and practice thus far. The second is 
cancer progression at the time of restaging after completion of preoperative LCRT. 
To date, there have been few reports on this issue. The third is early recurrence after 
TME following preoperative LCRT, the reason for which is thought to be the delayed 
systemic chemotherapy in the preoperative LCRT protocol. The fourth is cost-effec-
tiveness. The preoperative LCRT protocol takes 5 weeks. After a 6-8-week waiting 
period, surgery is performed. Therefore, it is more time-consuming than short-course 
chemoradiotherapy. To overcome these issues, total neoadjuvant treatment (TNT) 
modalities, performed using various protocols, have been conducted globally based 
on cumulative experience. We also attempted to discuss previous TNT protocols in 
this article. One treatment strategy is not sufficient for patients with varying clinical 
characteristics. Therefore, we should revisit current treatment strategies based on 
recent clinical experience.
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1  | CURRENT TRE ATMENT STR ATEGIES 
FOR LOC ALLY ADVANCED REC TAL C ANCER
Before discussing the treatment of locally advanced rectal cancer 
(LARC), we should define the rectum. In Japan, the rectum is di-
vided into the rectosigmoid (the sacral promontory to the inferior 
border of the second sacral vertebra), upper rectum (the second 
sacral vertebra to the peritoneal reflection), and lower rectum 
(the peritoneal reflection to the superior border of the puborec-
tal sling).1 However, the definition of the rectum is different in 
Japan from those in Western countries and Korea. Moreover, the 
definition differs even among Western countries. In the national 
comprehensive cancer network (NCCN) guidelines, the rectum is 
defined as the portion of the bowel located below the pelvic inlet 
(an imaginary line drawn from the sacral promontory to the top of 
the pubic symphysis) as determined by dedicated magnetic reso-
nance imaging (MRI) of the pelvis. The rectum is divided into the 
upper rectum (above the anterior peritoneal reflection), mid-rec-
tum (at the anterior peritoneal reflection), and lower rectum (below 
the anterior peritoneal reflection).2 In the European Society for 
Medical Oncology (ESMO) guideline, tumors with 15-cm distal ex-
tension from the anal margin (as measured by rigid sigmoidoscopy) 
are classified as rectal cancers. Cancers are categorized as low (up 
to 5 cm), middle (>5-10 cm), or high (>10 up to 15 cm).3 In Korea, we 
use a definition similar to that in the ESMO guideline, in which the 
rectum is divided into the upper, mid, and lower rectum by 4-5 cm. 
In this review article, we used the definition from the Western 
guideline, as most of the introduced studies and treatment strate-
gies were from Western countries.
Traditionally, preoperative long-course chemoradiotherapy 
(LCRT) combined with radiosensitizing chemotherapy followed by 
total mesorectal excision (TME) and postoperative adjuvant chemo-
therapy has been used for LARC in Western countries and Korea. 
In the German CAO/ARO/AIO-94 trial, neoadjuvant treatment, 
consisting of 50.4-Gy radiation in 28 fractions, with concurrent che-
motherapy and continuous 5-fluorouracil (FU) infusion, resulted in 
significantly better outcomes than adjuvant treatment in terms of 
lower local recurrence (LR) (6% vs 13%, P = .006) and lower toxicity 
rate (27% vs 40%, P = .001).4 Neoadjuvant CRT is better tolerated 
than postoperative CRT, allows curative resection after down-
staging, and results in improved sphincter preservation rates. The 
German trial established preoperative LCRT as the preferred con-
current option for LARC.
Several European studies have looked at the efficacy of preoper-
ative short-course radiotherapy (SCRT) (25 Gy over 5 days). The re-
sults of the Swedish Rectal Cancer Trial, evaluating the use of SCRT 
administered preoperatively for resectable rectal cancer, showed a 
survival advantage and a decreased rate of LR compared with the 
use of surgery alone.5 The Dutch TME trial on SCRT reported that 
10-year survival was significantly improved in patients with stage III 
disease and a negative circumference resection margin (CRM) in the 
RT plus surgery group compared to the surgery-only groups (50% vs 
40%, P = .032).6
Along with RT, adjuvant chemotherapy is a matter of debate. 
Adjuvant chemotherapy is currently recommended in patients with 
rectal cancer who have undergone upfront surgery and are in post-
operative pathologic stages II or III.7 Nevertheless, adjuvant chemo-
therapy remains controversial, especially in patients who undergo 
preoperative CRT, with no study to date having clearly delineated 
the role of adjuvant chemotherapy in this setting. To date, adjuvant 
5-FU has been demonstrated to improve survival; oxaliplatin-based 
adjuvant chemotherapy has recently been shown to improve dis-
ease-free survival (DFS) in patients with rectal cancer with ypStage 
II and III disease after preoperative LCRT.8
Currently, total neoadjuvant therapy (TNT) has been highlighted 
as the treatment modality for LARC. TNT is defined as chemother-
apy using cycles of induction or consolidation in conjunction with 
standard CRT prior to surgery. The rationale for TNT includes early 
introduction of systemic treatment to address micrometastases, 
earlier reversal of diverting ileostomy, decreased toxicity rates, and 
increased tumor regression that can enhance complete (R0) resec-
tion rates and optimize adaptive strategies and patient selection for 
organ preservation.9 In a recent systemic review and meta-analysis, 
TNT increased the risk of pathologic complete response (pCR) by 
39% (P = .01). Moreover, patients who received TNT and surgery had 
a better DFS (Hazard ratio [HR] = 0.75, 95% confidence interval [CI] 
0.52-1.07, P = .1) and OS (overall survival) (HR = 0.73, 95% CI 0.59-
0.9, P = .004) than those who received standard CRT.10
In this review, based on accumulated clinical experience, we 
would like to address a couple of issues that have proven very chal-
lenging in the treatment of patients with LARC.
2  | CHALLENGING ISSUES
2.1 | LARC with resectable liver metastases
In guidelines on colorectal cancer, if both distant metastases and 
the primary tumor are resectable, curative resection of the primary 
tumor is performed and resection of the distant metastases is con-
sidered.2,3,11 The NCCN guideline also recommends upfront chemo-
therapy as the primary treatment even in resectable synchronous 
liver metastases (LM).2 However, currently, there is no consensus 
regarding optimal management and practice.
In rectal cancer with synchronous LM, a more complex procedure 
for the determination of optimal treatment strategies is required, 
particularly when patients present with LARC. This is because local 
treatment with RT is definitely needed for tumor regression of the 
primary tumor. Delay of administration of systemic therapy has be-
come a great concern because of the potential progression of LM 
beyond resectability during preoperative LCRT. Accordingly, there 
is a need for early administration of preoperative systemic che-
motherapy and shortened duration of RT owing to the metastatic 
condition.12 Chemotherapeutic agents used in LCRT include 5-FU 
regimens that are used as radiosensitizers.13 The dose is too small 
for systemic control of LM.
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For systemic and local treatment simultaneously, we instituted 
our own “sandwich” protocol in our institution (Figure 1). This aimed 
to systemically control first LM; then, SCRT with delayed surgery 
was adopted for LARC. We administer four cycles of systemic che-
motherapy as induction chemotherapy, followed by SCRT for 5 days. 
Subsequently, additional chemotherapy of the same regimen can be 
administered during the waiting period to allow tumor regression. 
After restaging, simultaneous resection for primary rectal cancer 
and LM was performed. This protocol allows systemic chemother-
apy to be administered earlier, and surgery can be planned after the 
evaluation of tumor response at least 6 weeks after completion of 
SCRT. A case series of six patients with LARC with synchronous and 
potentially resectable distant metastases was reported in 2011.14 
The investigators reported that R0 resection was achieved, except 
for a primary tumor in one patient. Neither LR nor mortality was 
observed, and there were acceptable adverse events. This protocol 
can also be adopted in LARC with LM, even though they are un-
resectable. A phase II single-arm study for LARC with synchronous 
liver-only metastases was conducted.15 This study was focused on 
LARC with synchronous liver-only metastases (no number or size 
limitation of LM). Among 32 patients, surgical resection was per-
formed in 25 patients (78%), and an R0 resection rate of 63% for 
both sites was recorded. The tumor downstaging rate was 54%. We 
are still waiting for long-term outcomes in these patients.
In addition to a primary tumor-first approach, a liver-first ap-
proach was first described in 2006 in an effort to overcome pro-
gression of LM.16 The liver-first approach consists of upfront 
chemotherapy followed by liver resection and subsequent CRT and 
primary tumor resection. The theoretical basis is that prognosis of 
LM may depend more on LM than on the primary lesion. Possible 
benefits of the liver-first approach are the early use of systemic 
chemotherapy and minimization of progression of LM. Andrea 
et al reported comparable oncological outcomes of the liver-first and 
primary-first approaches (5-year DFS: 30% vs 29%; 5-year OS: 42% 
vs 55%, no statistical difference).17 Because there are various treat-
ment modalities, this remains a challenging issue despite the fact 
that a number of patients do not show LARC with synchronous LM.
2.2 | Cancer progression at the time of restaging 
after completion of preoperative LCRT
The second issue is the progression of the cancer at restaging after 
completion of preoperative LCRT. After 5 weeks of radiotherapy, 
6-8 weeks of waiting period is necessary to evaluate the tumor re-
sponse. With this restaging time, systemic failure can sometimes be 
observed. In this situation, depending on the tumor extent, treat-
ment strategies such as surgery for lesions or salvage chemotherapy 
may be implemented.
To date, there have been few reports on this issue because of the 
small number of patients. Choi et al reported this issue.18 Patients 
who developed distant metastases within 6 months after CRT were 
identified. The indications for preoperative LCRT were T4, CRM 
involved or threatened, or suggestive metastasis of a lateral pelvic 
lymph node (LN), defined as an LN beyond the TME plane such as 
iliac and obturator LNs, on initial staging. Among 107 patients who 
underwent neoadjuvant LCRT, seven (6.5%) developed early sys-
temic recurrence.
Recently, we investigated patients who had distant metastases 
during the restaging period after preoperative LCRT for LARC (un-
published). Patients with metastases at the initial diagnosis were 
excluded; 1.3% of patients showed distant metastases during the 
restaging period. They showed a high incidence of positive me-
sorectal LN, positive MR-CRM, and positive MR-extramural ve-
nous invasion (EMVI) during initial clinical staging on magnetic 
resonance imaging (MRI) (85.7%, 85.7%, and 71.4%, respectively). 
Poor response in the primary tumor was also observed (mrTRG 3 
[MRI-detected tumor regression grade]: 57.1%, mrTRG4: 35.7%, 
and mrTRG5: 7.1%).
For these patients, another treatment strategy should be ad-
opted at first. Unfortunately, risk factors for poor response have not 
been well studied. Further research on this issue is necessary. Proper 
treatment strategy when patients are expected to be poor respond-
ers should be considered. TNT including induction or consolidation 
chemotherapy can be a possible alternative.
2.3 | Early recurrence after TME following 
preoperative LCRT
Early recurrence occurring within one year after surgery for primary 
rectal cancer has been linked to systemic failure and poor survival.19 
Early recurrence reflects aggressive biologic behavior. This is the 
reason early systemic chemotherapy is necessary. Delayed systemic 
chemotherapy in the preoperative LCRT protocol can be the reason F I G U R E  1   Sandwich protocol
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for no benefit on OS, despite the fact that local control may have 
been obtained.20
Recently, EMVI has been studied in detail (Figure 2). EMVI is 
defined as tumor cells invading the veins beyond the muscularis 
propria; it is relatively common in T3-4 tumors.21 EMVI is closely 
associated with local and systemic recurrence.22 Studies have shown 
the advantages of high-resolution MRI in detecting EMVI.23 When 
we compared patients with and without mrEMVI after preoperative 
LCRT, significant differences were observed in terms of 5-year DFS 
(80.8% vs 57.8% P = .005) and 5-year systemic recurrence-free sur-
vival rates (86.9% vs 64.3%, P = .007). Furthermore, mrEMVI was 
a significant independent prognostic factor for systemic recurrence 
(HR: 3.321, 95% CI: 1.185-9.309, P = .022).24
For patients who show poor response to LCRT, consolidation 
chemotherapy consisting of systemic chemotherapy after LCRT be-
fore TME can be an option. The current treatment strategy for LARC 
is preoperative LCRT followed by TME, regardless of tumor regres-
sion grade, although poor prognosis can be expected. Marco et al25 
reported that consolidation chemotherapy increases compliance and 
DFS in patients with LARC. In terms of SCRT, Bujko et al reported 
comparable results of SCRT followed by consolidation chemother-
apy compared with preoperative LCRT (3-year DFS: 53% vs 52%, 
P = .85, 3-year OS 73% vs 65%, P = .046).26 The ongoing RAPIDO 
trial (NCT01558921)27 will report results soon. The RAPIDO trial 
compared two groups; the standard arm consists of LCRT preopera-
tively, followed by selective postoperative adjuvant chemotherapy. 
Postoperative chemotherapy is optional. The experimental arm con-
sists of SCRT followed by full-dose chemotherapy before surgery. In 
the experimental arm, no postoperative chemotherapy is prescribed. 
The hypothesis is that SCRT with neoadjuvant chemotherapy will in-
crease DFS and OS without compromising local control. The primary 
end-point is DFS at 3 years.
When we consider that most early recurrences after preopera-
tive LCRT followed by TME are systemic failures, systemic chemo-
therapy rather than radiation therapy should be adopted earlier. It 
is not clear if consolidation chemotherapy can prevent early sys-
temic failure. Further studies of risk factors for early systemic failure 
and treatment protocols including early administration of systemic 
chemotherapy are necessary. The standard preoperative LCRT is in-
sufficient in these patients.
2.4 | Cost-effectiveness
The preoperative LCRT protocol takes 5 weeks with treatment ad-
ministered for 5 days per week. After 6 to 8 weeks of the waiting 
period, surgery is performed. By contrast, SCRT requires only 5 days 
and a restaging period. There have been many reports comparing 
outcomes between LCRT and SCRT. However, there have been no 
reports on cost-effectiveness among treatment modalities.
Polish and Australian randomized studies have compared preop-
erative SCRT and immediate surgery with LCRT and delayed surgery 
in resectable rectal cancer.26,28 Ngan et al compared SCRT followed 
by early surgery and LCRT with delayed surgery.28 They found no 
difference in long-term outcomes (3-year LR 7.5% vs 4.4%, P = .24; 
5-year distant recurrence 27% vs 30%. P = .92; 5-year OS 74% vs 70% 
P = .62). The Stockholm III randomized study compared preopera-
tive SCRT and immediate surgery with SCRT and delayed surgery.29 
Surgical complications were more common in SCRT and immediate 
surgery (36% vs 28% HR: 0.70 CI: 0.51-0.96, P = .03). However, there 
was no difference in long-term outcomes. They suggested that SCRT 
with delayed surgery would be a useful alternative to conventional 
SCRT with immediate surgery. They also compared the SCRT regi-
men with LCRT with delay. The cumulative incidence of LR was not 
different among the groups. They concluded that LCRT with delay 
is similar to both SCRT regimens; however, it substantially prolongs 
the treatment time.
Recently, we started a prospective study called the ESCORT 
(Evaluation of Efficacy, Quality of Life, and Cost Effectiveness of 
Short-course Radiotherapy Followed by Capecitabine Plus Oxaliplatin 
Chemotherapy and TME for High-risk Rectal Cancer) (NCT03676517) 
trial (Figure 3). The main concept of this study is SCRT with delayed 
surgery. Two cycles of CapeOX are administered during the restaging 
period. We expect comparable oncologic results to those of previous 
studies. The strength of our study is the secondary outcome. We have 
a plan to obtain results for quality of life and cost-effectiveness. Our 
F I G U R E  2   MRI revealing EMVI 
positivity. A, before neoadjuvant LCRT, B, 
after neoadjuvant LCRT. EMVI, extramural 
venous invasion; LCRT, long-course 
chemoradiotherapy; MRI, magnetic 
resonance imaging
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hypothesis is that there will be better cost-effectiveness in patients 
using the ESCORT protocol with similar oncological outcomes. In cir-
cumstances of comparable outcomes between SCRT and LCRT, SCRT 
can be a good treatment protocol as well as LCRT based on Korean 
medical environment, in which there is a trend toward patients visiting 
large hospitals regardless of cost and distance.
Radiation toxicity and effectiveness should also be considered. 
The PROSPECT trial (NCT01515787) was designed to determine 
whether neoadjuvant chemotherapy with 5-FU and oxaliplatin 
(FOLFOX) could be used as an alternative to neoadjuvant chemo-
radiation without compromising treatment outcomes to spare these 
patients excess toxicity.30 This trial focused on avoiding unneces-
sary radiation and toxicity, especially low-risk LARC patients. Schrag 
et al31 conducted a single-institution pilot single-group phase II trial 
of 32 patients and suggested that it was safe to selectively omit 
chemoradiation for rectal cancer patients with evidence of clinical 
response to neoadjuvant FOLFOX chemotherapy. In our study (un-
published), neoadjuvant CRT was related to late anastomosis leakage 
complications compared with early anastomosis leakage (odds ratio 
[OR]: 3.032 CI: 1.947-4.722, P < .001). As for the choice between 
LCRT and SCRT, radiation toxicity should be considered when deter-
mining the treatment modality.
3  | SHIF TING TRE ATMENT STR ATEGY TO 
TOTAL NEOADJUVANT TRE ATMENT
Table 1 displays various TNT protocols discussed in this article. 
Several TNT protocols have been studied worldwide. Some proto-
cols comprising full doses of chemotherapy for 3-4 months followed 
by standard CRT and surgery as well as other courses of treatment, 
including SCRT after chemotherapy (induction chemotherapy), have 
been studied. Alternatively, some researchers have delivered chem-
otherapy immediately (consolidation chemotherapy) before surgery 
and after RT. Another group tried to omit RT according to the re-
sponse to induction chemotherapy. Target agents were also studied 
with various treatment strategies.10
In the Spanish GCR-3 randomized phase II trial,32 patients were 
randomized to receive CapeOX either before CRT or after surgery 
(induction chemotherapy group vs adjuvant chemotherapy group). 
Similar pathologic complete response rates were seen, and induction 
chemotherapy appeared to be less toxic and better tolerated. A sin-
gle-institution retrospective cohort analysis of patients with LARC 
compared traditional neoadjuvant CRT followed by resection with the 
TNT approach of induction chemotherapy followed by CRT before re-
section. Patients in the TNT group received a greater percentage of 
F I G U R E  3   ESCORT (Evaluation 
of Efficacy, Quality of Life and 
Cost Effectiveness of Short-course 
Radiotherapy Followed by Capecitabine 
Plus Oxaliplatin chemotherapy and TME 
for High-risk Rectal Cancer) protocol
TA B L E  1   Various total neoadjuvant treatment protocols in the review article
Author Study design Treatment group Primary outcome
Marco et al25 Nonrandomized Group I: neoadjuvant LCRT
Group II: Neoadjuvant LCRT – Consolidation CTx 
2cycles
Group III: Neoadjuvant LCRT – Consolidation CTx 
4cycles





Bujko et al26 Randomized neoadjuvant LCRT
vs. Conolidation CTx following SCRT
R0 resection
RAPIDO trial 27 Randomized neoadjuvant LCRT
vs. Conolidation CTx following SCRT
DFS after 3 years
Fernandez-Martos et al32 Nonrandomized neoadjuvant LCRT
vs. Induction CTx followed by LCRT
pCR rate
Cercek et al33 Retrospective neoadjuvant LCRT
vs. Induction CTx followed by LCRT
pCR rate
Group I:21%, group II:36%
CAO/ARO/AIO-12 trial35 Randomized Induction CTx followed by LCRT
vs. Conolidation CTx following SCRT
pCR rate
PROSPECT trial30 Randomized neoadjuvant LCRT
vs. induction CTx with or without RTx
R0 resection
DFS after 3 years
Note: Abbreviations: CTx, chemotherapy; DFS, disease free survival, RTx, radiotherapy; LCRT, long-course chemoradiation therapy; pCR, pathologic 
complete response; SCRT, short-course chemoradiation therapy.
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the planned chemotherapy dose than those in the adjuvant chemo-
therapy group. The complete response rates were 36% and 21% in the 
TNT and adjuvant chemotherapy groups, respectively.33 Possible ben-
efits of using systemic chemotherapy include the early prevention of 
eradication of micrometastases, higher rates of pathologic complete 
response, minimizing the length of time patients need for an ileos-
tomy, facilitating resection, and improving the tolerance and comple-
tion rates of chemotherapy. Another benefit can be patient selection 
for organ preservation. Since the introduction of the “watch-and-wait” 
protocol, non-operative management has been performed in selected 
patients with clinical complete response after TNT. An MSKCC-based 
multi-institutional phase II trial (NCT02008656) is being conducted 
to investigate the efficacies of TNT and selective non-operative man-
agement in LARC. Participants with clinical complete response will re-
ceive non-operative management according to the NCCN guidelines. 
Moreover, this study will demonstrate the possible benefit of TNT 
with respect to the “watch-and-wait” protocol.34
Even though short-term outcomes such as pCR, nodal downstag-
ing, and rate of R0 resection improve, data on long-term outcomes are 
limited. There are many ongoing studies in which specific design, op-
timal sequences, types, durations of chemotherapy, ideal timings, and 
dosages of RT are not defined. In CAO/ARO/AIO-12 (NCT02363374), 
group A (induction chemotherapy before CRT) was compared with 
group B (consolidation chemotherapy after CRT) to investigate the 
safety and efficacy of TNT sequences.35 Group B (CRT followed by 
consolidated chemotherapy) resulted in better compliance with CRT 
but worse compliance with chemotherapy than group A (induction che-
motherapy). A better pCR rate was seen in group B. To adopt the TNT 
protocol as the primary treatment modality, well-designed randomized 
controlled studies including molecular biomarkers will be necessary to 
determine the optimal treatment strategies according to patient char-
acteristics. Nevertheless, TNT may be the preferred option in patients 
with LARC who have high risk factors for poor prognosis.
4  | CONCLUSION
For the past decade, preoperative LCRT for LARC has been the 
standard treatment protocol for improving oncologic outcomes. 
With the accumulation of treatment experience, we identified 
groups of patients who did not show good tumor responses, with 
disease progression and early systemic failure as well. These findings 
suggest that one treatment plan cannot achieve all the oncological 
outcomes we desire.
Four robust consensus molecular subtypes (CMSs) were identi-
fied: CMS1, enriched for inflammatory/immune genes; CMS2, ca-
nonical; CMS3, metabolic; and CMS4, mesenchymal.36 CMS groups 
not only reflect cancer cell phenotypes but also microenvironmental 
features present in tumor tissue samples. Stage-independent prog-
nostic values and significant associations with multiple clinical and 
biological features were demonstrated. With respect to the chemo-
refractory setting, CMS2 (50%) followed by CMS4 (30%) were pre-
dominant in the CORRECT trial.37 The relatively consistent subtype 
distribution in first-line trials may explain the enrichment of CMS2 
and CMS4 over CMS3 and CMS1 after relapse in chemorefractory 
settings. Despite the potential clinical utility for outcome prediction 
or immune-targeted therapy development, their clinical implemen-
tation is challenging. Prospective molecularly stratified clinical trials 
should be encouraged.38 The rapid evolution of knowledge in cancer 
biology should be integrated at the individual level.39
Advances in technologies such as imaging and molecular typing, 
combined with updated TNT protocols, may result in better oncolog-
ical outcomes than current treatment strategies based on individual 
risk factors.
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